Maria
Sundvall
Docent, Institute of Biomedicine
Clinical Lecturer, Institute of Biomedicine
Researcher, Institute of Biomedicine
Senior Researcher, Institute of Biomedicine
MD PhD; Specialist Physician in Clinical Oncology
Areas of expertise
clinical oncology
breast and prostate cancer
targeted cancer therapeutics
cancer biology
cell signaling
posttranslational modifications
dna repair pathways
Biography
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Teaching
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Research
Dr. Sundvall has 20 years of experience in studying molecular mechanisms of cancer. Currently she is a principal investigator at University of Turku, and her group is focusing on investigating the role fo DNA repair pathways in prostate cancer. Links:
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
Publications
Proteolytic cleavage and phosphorylation of tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. (2006)
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))Signaling via ErbB2 and ErbB3 associates with resistance and Epidermal Growth Factor Receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells (2006)
Clinical Cancer Research
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells (2005)
Cancer Research
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))